| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Departments of Microbiology-Immunology and Pathology and The Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; and
Department of Pathology, University of Missouri, Kansas City, MO 64110
Captopril, an angiotensin-converting enzyme inhibitor, is widely used in the treatment of a variety of cardiomyopathies, but its effect on autoimmune myocarditis has not been addressed experimentally. We investigated the effect of captopril on myosin-induced experimental autoimmune myocarditis. A/J mice, immunized with syngeneic cardiac myosin, were given 75 mg/L of captopril in their drinking water. Captopril dramatically reduced the incidence and severity of myocarditis, which was accompanied by a reduction in heart weight to body weight ratio and heart weight. Captopril specifically interfered with cell-mediated immunity as myosin delayed-type hypersensitivity (DTH) was reduced, while anti-myosin Ab production was not affected. Captopril-treated, OVA-immunized mice also exhibited a decrease in OVA DTH. In myosin-immunized, untreated mice, injection of captopril directly into the test site also suppressed myosin DTH. Interestingly, captopril did not directly affect Ag-specific T cell responsiveness because neither in vivo nor in vitro captopril treatment affected the proliferation, IFN-
secretion, or IL-2 secretion by Ag-stimulated cultured splenocytes. These results indicate that captopril ameliorates experimental autoimmune myocarditis and may act, at least in part, by interfering with the recruitment of cells to sites of inflammation and the local inflammatory environment.
This article has been cited by other articles:
|
|
 |
|
  S. Duran-Barragan, G. McGwin Jr, L. M. Vila, J. D. Reveille, and G. S. Alarcon Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort Rheumatology, July 1, 2008; 47(7): 1093 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Arndt, S. K. Young, K. R. Poch, J. A. Nick, S. Falk, R. W. Schrier, and G. S. Worthen Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways J. Immunol., November 15, 2006; 177(10): 7233 - 7241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dalbeth, J. Edwards, S. Fairchild, M. Callan, and F. C. Hall The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis Rheumatology, January 1, 2005; 44(1): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsumoto, Y. Tsukada, A. Miyakoshi, H. Sakuma, and K. Kohyama C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy: Rescue from Death and Prevention of Dilated Cardiomyopathy by Chemokine Receptor DNA Therapy J. Immunol., September 1, 2004; 173(5): 3535 - 3541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shimizu, M. Miyoshi, K. Matsumoto, O. Goto, T. Imoto, and T. Watanabe The Effect of Central Injection of Angiotensin-Converting Enzyme Inhibitor and the Angiotensin Type 1 Receptor Antagonist on the Induction by Lipopolysaccharide of Fever and Brain Interleukin-1{beta} Response in Rats J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 865 - 873. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
